HCW Biologics (HCWB)

• Market cap: $20M
• 1 day: 8.72%
• 5 days: 32.06%
• 1 month: -52.60%
• 3 months: -26.75%
• 6 months: -55.10%
• Year to date: -62.58%
• 1 year: -62.89%
• 5 years: -92.87%
• 10 years: -92.87%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Employees: 45

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.14% less ownership

Funds ownership: 3.21% [Q2] → 3.06% (-0.14%) [Q3]

16% less funds holding

Funds holding: 19 [Q2] → 16 (-3) [Q3]

20% less capital invested

Capital invested by funds: $784K [Q2] → $626K (-$159K) [Q3]

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4